Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...

G enentech, a member of the Roche Group, announced results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart compared with a ...

Alternative splicing exhibits lineage-specific variability, with mammals and birds reaching the highest levels despite conserved intron-rich architectures, while unicellular eukaryotes and prokaryotes ...